SCHEMBL6495696

SCHEMBL6495696

Cc1ccc(-c2ccc(C)cc2C(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.58
CSNK2A1 P68400 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
MCL1 Q07820 1/20 0.55
CYP46A1 Q9Y6A2 1/20 0.50
PRKAB2 O43741 1/20 0.49
PRKAG1 P54619 1/20 0.49
PRKAA2 P54646 1/20 0.49
PRKAA1 Q13131 1/20 0.49
PRKAG3 Q9UGI9 1/20 0.49
PRKAG2 Q9UGJ0 1/20 0.49
PRKAB1 Q9Y478 1/20 0.49
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
FOLH1 Q04609 2/20 0.47
NOTUM Q6P988 1/20 0.47
POLB P06746 1/20 0.46
ALPL P05186 1/20 0.46
DHODH Q02127 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3733709 0.90 HDAC7 (0.60) HSD17B10CSNK2A1SMN1; SMN2CYP46A1HDAC7
SCHEMBL6499129 0.89 HSD17B10 (0.51) HSD17B10CSNK2A1SMN1; SMN2PRKAB2PRKAG1
SCHEMBL27999421 0.89 HSD17B10 (0.51) HSD17B10CSNK2A1SMN1; SMN2MCL1CYP46A1
SCHEMBL6492370 0.89 HSD17B10 (0.51) HSD17B10CSNK2A1SMN1; SMN2MCL1CYP46A1
SCHEMBL2561925 0.88 HSD17B1 (0.53) HSD17B10CSNK2A1SMN1; SMN2MCL1CYP46A1
SCHEMBL30832923 0.88 MCL1 (0.58) HSD17B10CSNK2A1SMN1; SMN2MCL1PRKAB2
SCHEMBL4621112 0.87 CSNK2A1 (0.65) HSD17B10CSNK2A1SMN1; SMN2MCL1HDAC7
SCHEMBL6490357 0.87 DHODH (0.60) HSD17B10SMN1; SMN2MCL1PRKAB2PRKAG1
SCHEMBL10079022 0.87 HSD17B10 (0.79) HSD17B10CSNK2A1SMN1; SMN2MCL1PRKAB2
SCHEMBL7245003 0.86 PRKAB2 (0.50) HSD17B10CSNK2A1SMN1; SMN2MCL1CYP46A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180194899-A1 PRECURSOR FOR POLYIMIDE AND USE THEREOF ETERNAL MATERIALS CO., LTD. (TW) 2018-07-12 US disclosed
US-20180148544-A1 PRECURSOR FOR POLYIMIDE AND USE THEREOF ETERNAL MATERIAL CO., LTD. (TW) 2018-05-31 US disclosed
US-20180148541-A1 POLYIMIDE PRECURSOR COMPOSITION AND USE THEREOF ETERNAL MATERIALS CO., LTD. (TW) 2018-05-31 US disclosed
US-9617223-B2 Base generator ETERNAL MATERIALS CO., LTD. (TW) 2017-04-11 US disclosed
US-9334369-B2 Polyimide precursor composition and preparation method and use thereof ETERNAL CHEMICAL CO., LTD. (TW) 2016-05-10 US disclosed
US-20160017105-A1 SOLVENT-CONTAINING DRY FILM AND METHOD FOR APPLYING THE SAME ON A SUBSTRATE ETERNAL MATERIALS CO., LTD. (TW) 2016-01-21 US disclosed
US-20140228512-A1 POLYIMIDES, COATING COMPOSITION FORMED THEREFROM AND USE THEREOF ETERNAL CHEMICAL CO., LTD. (TW) 2014-08-14 US disclosed
US-8673540-B2 Photosensitive polymides ETERNAL CHEMICAL CO., LTD. (TW) 2014-03-18 US disclosed
US-20130172494-A1 POLYIMIDE PRECURSOR COMPOSITION AND PREPARATION METHOD AND USE THEREOF ETERNAL CHEMICAL CO., LTD. (TW) 2013-07-04 US disclosed
US-20130172569-A1 BASE GENERATOR ETERNAL CHEMICAL CO., LTD. (TW) 2013-07-04 US disclosed
US-20130095426-A1 PHOTOSENSITIVE POLYMIDES ETERNAL CHEMICAL CO., LTD. (TW) 2013-04-18 US disclosed
US-20110212402-A1 PHOTOSENSITIVE RESIN COMPOSITION AND ITS APPLICATION ETERNAL CHEMICAL CO., LTD. (TW) 2011-09-01 US disclosed
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed
EP-0879814-B1 Triaromatic compounds, compositions containing them and uses thereof CT INTERNAT DE BR RECH S DERMA (FR) 2001-11-28 EP disclosed
EP-0879814-A1 Triaromatic compounds, compositions containing them and uses thereof CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1998-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172569-A1 BASE GENERATOR REV1, MUS81, PADI1 HSD17B10 3534/4885CSNK2A1 2463/4885SMN1; SMN2 2323/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HSD17B10 901/4885CSNK2A1 339/4885SMN1; SMN2 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.